NCT07585786Not yet recruiting
Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)
A Prospective, Single-Center, Observational Cohort Study to Evaluate the Long-Term (2-Year) Effects of Laparoscopic Splenectomy and Azygoportal Disconnection on Renal Function in Patients With Liver Cirrhosis, Portal Hypertension Bleeding
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether LSD can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 22 Apr 2026
- Start date
- 1 May 2026
- Primary completion date
- 28 Feb 2029
- Lead sponsor
- Northern Jiangsu People's Hospital
- Diseases
- High blood pressure
- NCT number
- NCT07585786
What you commit to
- Study type: Observational
- Planned participants: 30
- From 1 May 2026 to the primary completion date, 28 Feb 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection
- Hepatic encephalopathy or refractory ascites within 1 month before surgery
Other illness
- Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.)
- Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders
Other
- Child-Pugh Class C liver cirrhosis
- Pregnancy or lactation
- Poor compliance, inability to complete follow-up
Who the study is looking for
- Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)
- Splenomegaly and hypersplenism
- History of portal hypertension bleeding (esophageal and gastric variceal bleeding )
- Age 18-80 years, male or female
- Child-Pugh Class A or B liver function
- No history of primary renal disease or acute kidney injury (AKI)
- Signed written informed consent
- Ability to complete 24-month follow-up
Age in the registry: 18 years to 80 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.